AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 34223142 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up at 6 weeks
Number of subjects: 417
Study 34742368 — intervention group
Group type: EXPERIMENTAL
Intervention: QFR-guided strategy (PCI performed only if QFR ≤0.80)
Number of subjects: 3825
Study 34742368 — intervention group
Group type: COMPARATOR
Intervention: Angiography-guided strategy (PCI based on standard visual angiographic assessment)
Number of subjects: 3825
Study 35932386 — intervention group
Group type: EXPERIMENTAL
Intervention: Formulation A
Number of subjects: 30
Study 35932386 — intervention group
Group type: EXPERIMENTAL
Intervention: Formulation A (fed condition)
Number of subjects: 30
Study 35932386 — intervention group
Group type: EXPERIMENTAL
Intervention: Formulation A (multiple doses)
Number of subjects: 30
Study 35932386 — intervention group
Group type: COMPARATOR
Intervention: Formulation B
Number of subjects: 30
Study 33113440 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary alpha-lipoic acid (ALA) supplementation (300 mg/kg)
Number of subjects: 16
Study 33113440 — intervention group
Group type: COMPARATOR
Intervention: Basal diet (Control)
Number of subjects: 16
Study 36175782 — intervention group
Group type: COMPARATOR
Intervention: Tofersen
Number of subjects: 0
Study 33035141 — intervention group
Group type: EXPERIMENTAL
Intervention: Off-clamp surgery
Number of subjects: 249
Study 33035141 — intervention group
Group type: EXPERIMENTAL
Intervention: On-clamp surgery
Number of subjects: 249
Study 33035141 — intervention group
Group type: COMPARATOR
Intervention: Shift-on-clamp cases
Number of subjects: 249
Study 33035141 — intervention group
Group type: COMPARATOR
Intervention: Shift-off-clamp cases
Number of subjects: 249
Study 33035141 — intervention group
Group type: COMPARATOR
Intervention: On-clamp surgery per protocol
Number of subjects: 249
Study 32274889 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary radical radiotherapy, n=4,174
Number of subjects: 20350
Study 32274889 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostatectomy, n=1,210
Number of subjects: 20350
Study 32274889 — intervention group
Group type: EXPERIMENTAL
Intervention: Men age 65-74
Number of subjects: 20350
Study 32274889 — intervention group
Group type: EXPERIMENTAL
Intervention: All men with newly diagnosed locally advanced PCa
Number of subjects: 20350
Study 36293952 — intervention group
Group type: EXPERIMENTAL
Intervention: e-Problem-Based Learning (e-PBL) program
Number of subjects: 54
Study 36293952 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 54
Study 32693097 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention clinics (clinician education sessions and electronic health record tools)
Number of subjects: 386
Study 32693097 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision support tools (SmartSet and SmartText)
Number of subjects: 386
Study 32693097 — intervention group
Group type: COMPARATOR
Intervention: Control clinics (no training or tools provided)
Number of subjects: 386
Study 35244070 — intervention group
Group type: EXPERIMENTAL
Intervention: Nerve block therapy (NBT) + acupotomy
Number of subjects: 50
Study 35244070 — intervention group
Group type: COMPARATOR
Intervention: Nerve block therapy (NBT)
Number of subjects: 50
Study 34660811 — intervention group
Group type: EXPERIMENTAL
Intervention: Jinlida granules
Number of subjects: 138
Study 34660811 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 138
Study 34660811 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination treatment
Number of subjects: 138
Study 34660811 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 138
Study 34798147 — intervention group
Group type: EXPERIMENTAL
Intervention: Minocycline
Number of subjects: 266
Study 34798147 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib
Number of subjects: 266
Study 34798147 — intervention group
Group type: COMPARATOR
Intervention: Minocycline and Celecoxib
Number of subjects: 266
Study 36357855 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery
Number of subjects: 124
Study 36357855 — intervention group
Group type: COMPARATOR
Intervention: Nonsurgical care
Number of subjects: 124
Study 32542836 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 33301047 — intervention group
Group type: EXPERIMENTAL
Intervention: Housing First (HF)
Number of subjects: 87
Study 33301047 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 87
Study 33046465 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Community of Practice (VCoP) for 12 months
Number of subjects: 250
Study 33046465 — intervention group
Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 250
Study 33046465 — intervention group
Group type: EXPERIMENTAL
Intervention: VCoP
Number of subjects: 250
Study 35028951 — intervention group
Group type: EXPERIMENTAL
Intervention: HD + SHF + HP
Number of subjects: 10
Study 35028951 — intervention group
Group type: COMPARATOR
Intervention: High-volume postdilution olHDF
Number of subjects: 10
Study 33336850 — intervention group
Group type: EXPERIMENTAL
Intervention: ADO09
Number of subjects: 24
Study 33336850 — intervention group
Group type: COMPARATOR
Intervention: Lispro
Number of subjects: 24
Study 33336850 — intervention group
Group type: COMPARATOR
Intervention: Ins&Pram
Number of subjects: 24
Study 32431275 — intervention group
Group type: EXPERIMENTAL
Intervention: Transfluthrin (spatial repellent)
Number of subjects: 1332
Study 32431275 — intervention group
Group type: COMPARATOR
Intervention: Placebo (passive emanators)
Number of subjects: 1332
Study 33778937 — intervention group
Group type: EXPERIMENTAL
Intervention: Refeeding
Number of subjects: 0
Study 33778937 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal glucose injection
Number of subjects: 0
Study 33778937 — intervention group
Group type: COMPARATOR
Intervention: Glutamate antagonist (CNQX + refeeding)
Number of subjects: 0
Study 33778937 — intervention group
Group type: COMPARATOR
Intervention: Glutamate antagonist (CNQX + glucose)
Number of subjects: 0
Study 33789971 — intervention group
Group type: EXPERIMENTAL
Intervention: Osteopathic manipulative treatment (OMT) - two sessions
Number of subjects: 128
Study 33789971 — intervention group
Group type: COMPARATOR
Intervention: Control group - manipulations performed on a doll behind a screen
Number of subjects: 128
Study 33789971 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjusted OMT
Number of subjects: 128
Study 33789971 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 128
Study 34392573 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrogen peroxide topical solution 35% (H2 O2)
Number of subjects: 15
Study 34392573 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryosurgery
Number of subjects: 15
Study 35549757 — intervention group
Group type: EXPERIMENTAL
Intervention: Qingpeng ointment applied topically at involved joints twice a day for consecutive 7 days
Number of subjects: 206
Study 35549757 — intervention group
Group type: COMPARATOR
Intervention: Placebo ointment applied topically at involved joints twice a day for consecutive 7 days
Number of subjects: 206
Study 33038078 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupressure applied to CV‐23, SJ‐17, Kid‐1 acupuncture points for 15 min three times a week for six weeks
Number of subjects: 60
Study 33038078 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupressure applied to CV‐23, SJ‐17, Kid‐1 acupuncture points
Number of subjects: 60
Study 33038078 — intervention group
Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 60
Study 32221093 — intervention group
Group type: EXPERIMENTAL
Intervention: SBRT with sorafenib
Number of subjects: 54
Study 32221093 — intervention group
Group type: COMPARATOR
Intervention: SBRT alone
Number of subjects: 54
Study 35351697 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided PENG block
Number of subjects: 92
Study 35351697 — intervention group
Group type: COMPARATOR
Intervention: Ultrasound-guided femoral nerve block
Number of subjects: 92
Study 32557634 — intervention group
Group type: EXPERIMENTAL
Intervention: Attentional bias toward affective pictorial stimuli
Number of subjects: 97
Study 32557634 — intervention group
Group type: EXPERIMENTAL
Intervention: Attentional bias
Number of subjects: 97
Study 32557634 — intervention group
Group type: COMPARATOR
Intervention: Control group (men without a history of criminal offending)
Number of subjects: 97
Study 32098501 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide 2 mg
Number of subjects: 14752
Study 32098501 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14752
Study 32098501 — intervention group
Group type: EXPERIMENTAL
Intervention: Any glucose-lowering medication
Number of subjects: 14752
Study 32098501 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfonylurea
Number of subjects: 14752
Study 32098501 — intervention group
Group type: EXPERIMENTAL
Intervention: All glucose-lowering medications
Number of subjects: 14752
Study 32098501 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardioprotective glucose-lowering agents
Number of subjects: 14752
Study 36096147 — intervention group
Group type: EXPERIMENTAL
Intervention: RTS,S/AS01E malaria vaccine
Number of subjects: 0
Study 33811730 — intervention group
Group type: EXPERIMENTAL
Intervention: Permanent polymer zotarolimus-eluting stent (PP-ZES)
Number of subjects: 304
Study 33811730 — intervention group
Group type: COMPARATOR
Intervention: Polymer-free amphilimus-eluting stent (PF-AES)
Number of subjects: 304
Study 33811730 — intervention group
Group type: EXPERIMENTAL
Intervention: Permanent polymer zotarolimus-eluting stent (PP-ZES) in insulin-treated diabetics
Number of subjects: 304
Study 33811730 — intervention group
Group type: COMPARATOR
Intervention: Polymer-free amphilimus-eluting stent (PF-AES) in insulin-treated diabetics
Number of subjects: 304
Study 34705586 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive resistance exercise training (PRET) for 6 months
Number of subjects: 73
Study 34705586 — intervention group
Group type: EXPERIMENTAL
Intervention: miR-19b-3p overexpression in human skeletal muscle cells in vitro
Number of subjects: 73
Study 34705586 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of circulating and skeletal muscle miR-19b-3p expression between young and old mice
Number of subjects: 73
Study 34705586 — intervention group
Group type: EXPERIMENTAL
Intervention: Differential expression of six miRNAs (including miR-19b-3p) between Gainers and Losers
Number of subjects: 73
Study 35123510 — intervention group
Group type: EXPERIMENTAL
Intervention: Macitentan treatment
Number of subjects: 0
Study 35123510 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 34510021 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-time visual feedback of the individual's own neck
Number of subjects: 23
Study 34510021 — intervention group
Group type: COMPARATOR
Intervention: Observing a book
Number of subjects: 23
Study 34505222 — intervention group
Group type: EXPERIMENTAL
Intervention: Transversus Abdominis Plane (TAP) block
Number of subjects: 174
Study 34505222 — intervention group
Group type: COMPARATOR
Intervention: Local Wound Infiltration (LWI)
Number of subjects: 174
Study 32145463 — intervention group
Group type: EXPERIMENTAL
Intervention: Processing of metric vs topological relations
Number of subjects: 0
Study 32145463 — intervention group
Group type: EXPERIMENTAL
Intervention: Processing of exact vs co‐exact relations
Number of subjects: 0
Study 33838078 — intervention group
Group type: EXPERIMENTAL
Intervention: Team Clinic (shared medical appointment model)
Number of subjects: 86
Study 33838078 — intervention group
Group type: COMPARATOR
Intervention: Traditional clinic visits (control group)
Number of subjects: 86
Study 33080371 — intervention group
Group type: EXPERIMENTAL
Intervention: AED-equipped drone delivery
Number of subjects: 35
Study 33080371 — intervention group
Group type: COMPARATOR
Intervention: Public access AED search
Number of subjects: 35
Study 35543102 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept (25 mg twice weekly for 16 weeks)
Number of subjects: 80
Study 35543102 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 33535474 — intervention group
Group type: EXPERIMENTAL
Intervention: BRAINballs program (conducted twice a week)
Number of subjects: 55
Study 33535474 — intervention group
Group type: COMPARATOR
Intervention: BRAINballs program
Number of subjects: 55
Study 33218845 — intervention group
Group type: EXPERIMENTAL
Intervention: Biostimulant formulation 2 at a dosage of 0.25 kg ha-1
Number of subjects: 11
Study 33218845 — intervention group
Group type: EXPERIMENTAL
Intervention: Biostimulant formulations (F1, F2, F3) at dosages of 0.25, 0.50, and 1.0 kg ha-1
Number of subjects: 11
Study 33218845 — intervention group
Group type: COMPARATOR
Intervention: Water-stressed control
Number of subjects: 11
Study 33218845 — intervention group
Group type: COMPARATOR
Intervention: Control without water deficit
Number of subjects: 11
Study 32744035 — intervention group
Group type: EXPERIMENTAL
Intervention: Qizhukangxian granules (QG)
Number of subjects: 120
Study 32744035 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 36448196 — intervention group
Group type: EXPERIMENTAL
Intervention: Older prisoner Health and Social Care Assessment and Plan (OHSCAP)
Number of subjects: 26
Study 36448196 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 26
Study 33653286 — intervention group
Group type: EXPERIMENTAL
Intervention: MultiMove intervention (dance-therapeutic component combined with motor-cognitive, strength, and flexibility exercises)
Number of subjects: 100
Study 33653286 — intervention group
Group type: EXPERIMENTAL
Intervention: MultiMove intervention
Number of subjects: 100
Study 32472840 — intervention group
Group type: EXPERIMENTAL
Intervention: Brains Ahead! intervention (psychoeducational session with written take-home information and follow-up telephone call(s))
Number of subjects: 124
Study 32472840 — intervention group
Group type: COMPARATOR
Intervention: Usual care (concise information brochure)
Number of subjects: 124
Study 35608270 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg/ml dilution of vancomycin
Number of subjects: 14
Study 35608270 — intervention group
Group type: COMPARATOR
Intervention: 20 mg/ml dilution of vancomycin
Number of subjects: 14
Study 36296983 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactiplantibacillus plantarum OLL2712 (heat-treated cells)
Number of subjects: 78
Study 36296983 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 78
Study 33207259 — intervention group
Group type: EXPERIMENTAL
Intervention: Brolucizumab
Number of subjects: 1817
Study 33207259 — intervention group
Group type: COMPARATOR
Intervention: Aflibercept
Number of subjects: 1817
Study 35073733 — intervention group
Group type: EXPERIMENTAL
Intervention: BEMPEG plus NIVO
Number of subjects: 0
Study 35073733 — intervention group
Group type: COMPARATOR
Intervention: NIVO alone
Number of subjects: 0
Study 33665685 — intervention group
Group type: EXPERIMENTAL
Intervention: Ertugliflozin (5 mg or 15 mg)
Number of subjects: 8246
Study 33665685 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8246
Study 33317565 — intervention group
Group type: EXPERIMENTAL
Intervention: Peanut protein (PP) supplement (75 total g powder providing 30 g protein, >9.2 g essential amino acids, 315 kcal; n=20)
Number of subjects: 39
Study 33317565 — intervention group
Group type: COMPARATOR
Intervention: Control (CTL; no supplement; n=19)
Number of subjects: 39
Study 33317565 — intervention group
Group type: EXPERIMENTAL
Intervention: Peanut protein (PP) supplement
Number of subjects: 39
Study 33317565 — intervention group
Group type: EXPERIMENTAL
Intervention: Peanut protein (PP) supplement (10-week group)
Number of subjects: 39
Study 34837651 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole peanut (WP)
Number of subjects: 24
Study 34837651 — intervention group
Group type: EXPERIMENTAL
Intervention: Skinned peanut (SP)
Number of subjects: 24
Study 34837651 — intervention group
Group type: COMPARATOR
Intervention: No peanut (NP)
Number of subjects: 24
Study 32293438 — intervention group
Group type: EXPERIMENTAL
Intervention: Doctors
Number of subjects: 360
Study 32293438 — intervention group
Group type: EXPERIMENTAL
Intervention: Allied Health Professionals (AHPs)
Number of subjects: 360
Study 32293438 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurses
Number of subjects: 360
Study 32293438 — intervention group
Group type: EXPERIMENTAL
Intervention: AHPs
Number of subjects: 360
Study 32293438 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurses and AHPs
Number of subjects: 360
Study 32293438 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervisors
Number of subjects: 360
Study 33686147 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI-based clinical-radiomic model
Number of subjects: 72
Study 34373374 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-guidewire technique with MagicTome (MDGT)
Number of subjects: 28
Study 34373374 — intervention group
Group type: COMPARATOR
Intervention: Conventional double-guidewire technique (CDGT)
Number of subjects: 28
Study 33465382 — intervention group
Group type: EXPERIMENTAL
Intervention: Abdominal massage using 'I LOV U' method along with lifestyle education, 15 min, twice daily for 10 days.
Number of subjects: 68
Study 33465382 — intervention group
Group type: EXPERIMENTAL
Intervention: Abdominal massage using 'I LOV U' method along with lifestyle education.
Number of subjects: 68
Study 33465382 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention).
Number of subjects: 68
Study 32860032 — intervention group
Group type: EXPERIMENTAL
Intervention: Icosapent ethyl (IPE) 4 g/day
Number of subjects: 80
Study 32860032 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 32860032 — intervention group
Group type: EXPERIMENTAL
Intervention: Icosapent ethyl (IPE)
Number of subjects: 80
Study 35148442 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote person-centred care (PCC) intervention conducted by health care professionals (HCPs)
Number of subjects: 11
Study 35148442 — intervention group
Group type: EXPERIMENTAL
Intervention: Question-driven narrative sequences guided by the HCP
Number of subjects: 11
Study 35148442 — intervention group
Group type: EXPERIMENTAL
Intervention: Completed narrative sequences driven by the patient and collaborative narrative sequences
Number of subjects: 11
Study 34853363 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 (2000 IU/day cholecalciferol)
Number of subjects: 3424
Study 34853363 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3424
Study 34021915 — intervention group
Group type: EXPERIMENTAL
Intervention: IV dexamethasone (2 mL, 8 mg)
Number of subjects: 37
Study 34021915 — intervention group
Group type: COMPARATOR
Intervention: Placebo (2 mL IV solution)
Number of subjects: 37
Study 32081056 — intervention group
Group type: EXPERIMENTAL
Intervention: Herbal combination
Number of subjects: 150
Study 32081056 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 150
Study 32081056 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study 35306269 — intervention group
Group type: COMPARATOR
Intervention: Brief Intervention (BI)
Number of subjects: 440
Study 35306269 — intervention group
Group type: COMPARATOR
Intervention: Combined Intervention (CoI)
Number of subjects: 440
Study 35306269 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard of Care (SOC)
Number of subjects: 440
Study 33485354 — intervention group
Group type: EXPERIMENTAL
Intervention: Texas Sprouts intervention (n = 1412 children)
Number of subjects: 3135
Study 33485354 — intervention group
Group type: COMPARATOR
Intervention: Control (delayed intervention, n = 1412 children)
Number of subjects: 3135
Study 33485354 — intervention group
Group type: EXPERIMENTAL
Intervention: Texas Sprouts intervention
Number of subjects: 3135
Study 33485354 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 3135
Study 32866967 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (2 g daily)
Number of subjects: 262
Study 32866967 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 262
Study 35944104 — intervention group
Group type: EXPERIMENTAL
Intervention: Total intravenous anesthesia using propofol (Group T)
Number of subjects: 60
Study 35944104 — intervention group
Group type: COMPARATOR
Intervention: Inhalation general anesthesia using sevoflurane (Group I)
Number of subjects: 60
Study 35944104 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Group T and Group I)
Number of subjects: 60
Study 33313898 — intervention group
Group type: EXPERIMENTAL
Intervention: Upadacitinib (UPA) monotherapy (15 mg, 30 mg)
Number of subjects: 1593
Study 33313898 — intervention group
Group type: COMPARATOR
Intervention: MTX
Number of subjects: 1593
Study 32745732 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartphone application for medication adherence (6 months)
Number of subjects: 1000
Study 32745732 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 1000
Study 32745732 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartphone application usage
Number of subjects: 1000
Study 32745732 — intervention group
Group type: EXPERIMENTAL
Intervention: Secondary outcomes (not specified as intervention or control)
Number of subjects: 1000
Study 33276251 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate/salmeterol MDI HFA (250 μg/50 μg, twice daily)
Number of subjects: 231
Study 33276251 — intervention group
Group type: COMPARATOR
Intervention: Fluticasone propionate/salmeterol DPI (500 μg/50 μg, twice daily)
Number of subjects: 231
Study 33023473 — intervention group
Group type: EXPERIMENTAL
Intervention: Eptinezumab 100 mg
Number of subjects: 1072
Study 33023473 — intervention group
Group type: EXPERIMENTAL
Intervention: Eptinezumab 300 mg
Number of subjects: 1072
Study 33023473 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1072
Study 33023473 — intervention group
Group type: EXPERIMENTAL
Intervention: Eptinezumab (both doses)
Number of subjects: 1072
Study 35544095 — intervention group
Group type: COMPARATOR
Intervention: Dihydroartemisinin-piperaquine only
Number of subjects: 80
Study 35544095 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquine plus tafenoquine 0.42 mg/kg
Number of subjects: 80
Study 35544095 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquine plus tafenoquine 0.83 mg/kg
Number of subjects: 80
Study 35544095 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquine plus tafenoquine 1.66 mg/kg
Number of subjects: 80